Infectious Diseases
Scrip spoke with CMO Dietmar Berger about his views on diversifying Gilead’s virology, oncology and immunology R&D efforts through both in-house research and external innovation.
At a recent discussion in South Korea, CEPI and other participants explored ways to discover new health cooperation models that go beyond traditional aid approaches and to strengthen Korea’s role.
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.
While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.
The European Medicines Agency has begun evaluating the EU marketing applications for a new batch of drugs, including products from Incyte, Sanofi and Novo Nordisk that target hidradenitis suppurativa, rabies and hemophilia A, respectively.
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
While the European Medicines Agency’s human medicines committee voted in favor of EU approval for 10 new products, it reaffirmed its previous decision not to grant Aqneursa new active substance status.
As trials of phage therapies for bacterial infections increase, the European Medicines Agency has proposed quality requirements in marketing applications for such products. Companies in this field include Locus Biosciences, Armata Pharmaceuticals, TechnoPhage, Phiogen, Medea Biopharma and BiomX.
The company is discontinuing congenital CMV development for its mRNA-1647 vaccine but still running a Phase II trial in bone marrow transplant patients.
The National Health Service said the roll out of ViiV Healthcare’s Apretude would bring England closer to its aim of becoming the first country in the world to end HIV transmissions by 2030.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.